Loading...
XCNQ
CHGX
, Last price  
CAD
Name

Chitogenx Inc

Chart & performance

D1W1MN
XCNQ:CHGX chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
24.15%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-2m
L-75.06%
-927,880-1,661,048-2,021,659-2,398,627-2,488,000-3,772,000-4,921,000-6,230,000-1,554,000
CFO
-1m
L-68.44%
23,112-1,699,018-1,919,863-1,384,682-1,591,000-2,981,000-3,220,000-3,197,000-1,009,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ChitogenX Inc. is a biologics firm focused on orthopedic and sports medicine, committing its efforts to pioneering novel soft tissue repair technologies. The company's primary objective is to elevate the efficacy of sports medicine surgical procedures through its research and development. Its developmental pipeline includes a range of specialized products: Ortho-R, a specific formulation designed for rotator cuff injuries; Ortho-M, a biopolymer addressing meniscus repair; Ortho-C, another biopolymer for the regeneration of articular cartilage; and Ortho-V, a biopolymer developed to facilitate the healing of osteoarthritis. Additionally, they are advancing ORTHO-T, a biopolymer formulation engineered for tendon healing and regeneration. Previously known as Ortho Regenerative Technologies Inc., the company adopted its current name, ChitogenX Inc., in September of 2022. Established in 2015, ChitogenX maintains its headquarters in Kirkland, Canada.

Key people

Steven Saviuk
Executive Co-Chairman of the Board
Executive Co-Chairman of the Board, Acting Chief Executive Officer
Jeff Skinner
Vice President - Business Development
Benedek Simo
Corporate Controller · since 2018
Michael Daro Buschmann
Director
IPO date
Oct 10, 2017
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑012023‑012022‑012021‑012020‑012019‑012018‑012017‑01
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT